We have examined the effect of CCL5- or CCR5-blockers administered as single agents or in combination with a murine PDGFRβ-directed treatment, this strategy being currently under clinical evaluation for the treatment of CRC cancers. This evidence concerns the gene PDGFRB and cancer.